Clinicopathologic Characteristics and Therapeutic Outcomes of Primary Gastrointestinal Non-Hodgkin's Lymphomas: 10 Years of Experience from a Single Center in Eastern Anatolia

被引:9
作者
Erkurt, Mehmet Ali [1 ]
Aydogdu, Ismet [1 ]
Kuku, Irfan [1 ]
Kaya, Emin [1 ]
Basaran, Yalcin [2 ]
机构
[1] Inonu Univ, Dept Hematol, Fac Med, Malatya, Turkey
[2] Gulhane Mil Med Acad, Dept Internal Med, Ankara, Turkey
关键词
Gastrointestinal non-Hodgkin's lymphoma; Prognostic factors; Clinicopathologic features; Survival; PRIMARY GASTRIC-LYMPHOMA; GERMAN MULTICENTER; TRACT LYMPHOMA; FEATURES; CHEMOTHERAPY; PROGNOSIS; WORKSHOP; SURGERY; STOMACH; TISSUE;
D O I
10.1159/000226295
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this retrospective study was to report the clinicopathological data and the treatment outcomes in patients with primary gastrointestinal non-Hodgkin's lymphoma. Patients and Methods: We carried out a retrospective analysis of 41 patients (22 females, 18 males, median age 58 and range 18-90 years) who presented to our department with histopathological diagnosis of primary gastrointestinal non-Hodgkin's lymphoma between 1995 and 2004. Results: The stomach was the most common extranodal site and was seen in 25 of 41 (61%) patients. At presentation 28 (68.3%) patients had gastrointestinal symptoms while 27 (65.9%) had B symptoms. The range of follow-up was 2-84 months with a median of 9 months. The overall survival rate was 3 years for 25 (61.2%) patients. The 3-year overall survival rate was better in patients with early-stage disease (stages I and II1) who were treated with surgery plus chemotherapy and/or radiation therapy than in those treated with chemotherapy alone (91.6 vs. 50%, p < 0.05). The disease had a significant impact on both the progression-free survival and overall survival rates. Conclusion: Our data showed that surgical resection prior to postoperative chemotherapy was a better option for patients with early-stage disease with better patient survival. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:399 / 406
页数:8
相关论文
共 30 条
[1]   Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma [J].
Avilés, A ;
Neri, N ;
Nambo, MJ ;
Huerta-Guzman, J ;
Cleto, S .
MEDICAL ONCOLOGY, 2006, 23 (02) :295-300
[2]   Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach -: Results of a controlled clinical trial [J].
Avilés, A ;
Nambo, MJ ;
Neri, N ;
Talavera, A ;
Cleto, S .
MEDICAL ONCOLOGY, 2005, 22 (01) :57-62
[3]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[4]   PRIMARY B-CELL GASTRIC LYMPHOMA - A CLINICOPATHOLOGICAL STUDY OF 145 PATIENTS [J].
COGLIATTI, SB ;
SCHMID, U ;
SCHUMACHER, U ;
ECKERT, F ;
HANSMANN, ML ;
HEDDERICH, J ;
TAKAHASHI, H ;
LENNERT, K .
GASTROENTEROLOGY, 1991, 101 (05) :1159-1170
[5]   NON-HODGKINS-LYMPHOMA OF THE GASTROINTESTINAL-TRACT - A POPULATION-BASED ANALYSIS OF INCIDENCE, GEOGRAPHIC-DISTRIBUTION, CLINICOPATHOLOGICAL PRESENTATION FEATURES, AND PROGNOSIS [J].
DAMORE, F ;
BRINCKER, H ;
GRONBAEK, K ;
THORLING, K ;
PEDERSEN, M ;
JENSEN, MK ;
ANDERSEN, E ;
PEDERSEN, NT ;
MORTENSEN, LS .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1673-1684
[6]  
DEVESA SS, 1992, CANCER RES, V52, pS5432
[7]  
DRAGOSICS B, 1985, CANCER-AM CANCER SOC, V55, P1060, DOI 10.1002/1097-0142(19850301)55:5<1060::AID-CNCR2820550523>3.0.CO
[8]  
2-8
[9]   Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin's lymphomas in central Anatolia, in Turkey [J].
Eser, B ;
Kaplan, B ;
Unal, A ;
Canoz, Z ;
Altuntas, F ;
Sari, HI ;
Er, O ;
Ozkan, M ;
Kucuk, C ;
Arar, M ;
Gursoy, S ;
Cetin, M .
YONSEI MEDICAL JOURNAL, 2006, 47 (01) :22-33
[10]  
GOBBI PG, 1990, CANCER-AM CANCER SOC, V65, P2528, DOI 10.1002/1097-0142(19900601)65:11<2528::AID-CNCR2820651123>3.0.CO